One Pager as on January 31, 2025
![]() | Selection of the next potential winners through the Equity Investment Process# |
![]() | High conviction focused portfolio with strong risk management processes |
![]() | Potential to generate relatively better risk adjusted returns |
#It is an internal process framework to optimize stock selection based on growth, cashflow generation, management and valuation
Sector | MMFF* | Nifty 500 TRI |
Financial Services | 32.67% | 29.29% |
Oil Gas & Consumable Fuels | 14.43% | 7.64% |
Fast Moving Consumer Goods | 11.23% | 7.00% |
Construction Materials | 6.63% | 2.09% |
Information Technology | 6.27% | 10.46% |
*Mahindra Manulife Focused Fund
Data as on January 31, 2025
Security | % to Net Assets |
ICICI Bank Limited | 7.98% |
HDFC Bank Limited | 7.67% |
Reliance Industries Limited | 6.54% |
State Bank of India | 5.85% |
ITC Limited | 5.76% |
Grasim Industries Limited | 4.44% |
Kotak Mahindra Bank Limited | 4.29% |
Infosys Limited | 4.11% |
Larsen & Toubro Limited | 4.05% |
Indus Towers Limited | 3.94% |
Total | 54.64% |
Fresh Additions | Complete Exits |
Security | Security |
Bajaj Finance Limited | HCL Technologies Limited |
ITC Hotels Limited * | Thomas Cook (India) Limited |
Trent Limited | United Spirits Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio
changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager
may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult
their financial, tax and other advisors before taking any investment decision(s). Data as on January 31, 2025
Turnover Ratio (Last 1 year) | 0.41 |
Standard Deviation | 13.60% |
Beta | 0.91 |
Sharpe Ratio# | 0.81 |
Jenson's Alpha | 0.3185 |
#Risk-free rate assumed to be 6.65% (MIBOR as on 31-01-25) - Source:www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on January 31, 2025
^Benchmark ^^Additional Benchmark. Inception/Allotment date: 17-Nov-20.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period. Ms. Fatema Pacha is managing this scheme since December 21, 2020
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 17-Nov-20.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Krishna Sanghavi manages 4 scheme and Ms. Fatema Pacha manages 8 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on January 31, 2025
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment in equity and equity
related instruments in concentrated
portfolio of maximum 30 stocks
across market capitalziation.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.